The missing link between data generation and unleashing it to power automation often lies in well-governed cloud infrastructure.
- Will FDA's One-Day Inspection Pilot Stand The Test Of Time?
- The Next Frontier In Women's Cancer Care: Combining Cell Therapy With Immuno-Oncology
- Spine Care Redefined: Autologous Cell Therapy For Degenerative Disc Disease
- A Multi-Agent Audit Intelligence Framework For CDMO Quality Oversight
- Why Contamination Control By Design Should Matter To Your CDMO
- Repeating Sanofi's Ballroom Design On Two Continents
- Early CDMO Engagement For Cell Therapies? CellProthera's CEO Thinks Not
- Closing The MES Value Gap: Why Technology Isn't The Problem
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Assessment Of Compound Toxicity Effects With High-Content Imaging
3D cellular models and bioprinting enhance drug safety predictions and offer precise spatial control. Explore an automated method for generating liver models to improve reproducibility and reliability in toxicity testing.
-
Quality Assurance In IVT RNA Vaccine Development Using Electrophoresis
Discover advanced solutions for IVT RNA synthesis, focusing on enhancing fidelity in throughput, innovative technologies, and methodologies to optimize your RNA research and development processes.
-
USP <665> Becomes Official On May 1, 2026. Are You Ready?
With USP <665> becoming official on May 1, 2026, proactive preparation is essential to ensure compliance and prevent delays, regulatory observations, or supply chain disruptions.
-
Microbial Recovery And Flow Performance With Membranes
Compare membrane materials and pore sizes to assess their impact on flow rate and microbial recovery. See how fast filtration and ≥90% organism recovery offer guidance for selecting reliable membranes.
-
Future-Proofing Life Sciences Manufacturing: 2025 CDMO Trends
Review contract manufacturing's evolution, driven by technological advancements and regulatory changes, and how CMOs and CDMOs are navigating opportunities and challenges.
-
Difco TC Yeastolate Ultra-Filtered (TCY UF) In Scale-Up Optimization
Explore how Difco™ TC Yeastolate ultra-filtered (TCY UF) enabled over 100% improvement in titer for CHO cell culture through feed optimization and bioreactor scalability in a real-world application.
-
Building A High-Quality IND From Scratch With Strategic Gap Analysis
A biotech sponsor lacking in-house regulatory expertise engaged a partner to obtain strategic regulatory review, medical writing, project management, and electronic publishing (eCTD).
-
A Scalable Manufacturing Platform For The Purification Of Stem Cell Derived Exosomes
EV production scale increases require paired robust, scalable, and cost-effective downstream processes. Process parameters can be tailored for therapeutic exosome programs and allow for maximum exosome recovery.
-
The Art Of Phosphitylation
Phosphorylation is key for bioactives, with phosphoramidites favored for high selectivity. Discover how choosing specific protecting groups and new technologies fine-tunes the synthesis process.
-
Development To Large-Scale cGMP Production
For manufacturers working with a dry powder medium (DPM), early consultation with a supplier can increase the likelihood of success. Uncover a two-phase scale-up strategy for the production of DPM.
NEWSLETTER ARCHIVE
- 05.22.26 -- Scaling RNA & LNP Manufacturing With Smarter Analytics
- 05.22.26 -- Inside March Biosciences' CD5-Targeting CAR-T Approach
- 05.21.26 -- Advancing Bioprocessing: Perfusion And Process Intensification Across Modalities
- 05.21.26 -- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- 05.20.26 -- Streamlined Lentiviral Characterization And QC With Digital PCR
- CGT Manufacturing Shifts From Capacity To Strategy
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections